Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update
August 10, 2023 07:00 ET
|
Immunocore Holdings Limited
Immunocore Reports Second Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £45.5 million ($57.8 million) in 2Q 2023; new launches in Italy, Austria,...
Immunocore to report second quarter 2023 financial results and host call on August 10, 2023
August 03, 2023 08:00 ET
|
Immunocore Holdings Limited
Immunocore to report second quarter 2023 financial results and host call on August 10, 2023 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 03 August 2023) Immunocore...
Immunocore presents additional ctDNA data from the KIMMTRAK Phase 3 trial at ASCO
June 03, 2023 07:00 ET
|
Immunocore Holdings Limited
Early on-treatment ctDNA reduction in stable disease patients treated with KIMMTRAK was associated with longer overall survival (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, 3...
Immunocore Reports First Quarter 2023 Financial Results and Provides Business Update
May 10, 2023 07:00 ET
|
Immunocore Holdings Limited
Immunocore Reports First Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £42.1 million ($52.0 million) in Q1 2023, with continued commercial expansion ...
Immunocore to present at the Bank of America Securities 2023 Health Care Conference
May 03, 2023 16:30 ET
|
Immunocore Holdings Limited
Immunocore to present at the Bank of America Securities 2023 Health Care Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 03 May 2023) Immunocore Holdings Plc...
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival
April 18, 2023 07:00 ET
|
Immunocore Holdings Limited
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival In the Phase 3 trial, early on-treatment ctDNA reduction was strongly associated...
Immunocore to present at the 22nd Annual Needham Virtual Healthcare Conference
April 11, 2023 07:00 ET
|
Immunocore Holdings Limited
Immunocore to present at the 22nd Annual Needham Virtual Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 April 2023) Immunocore Holdings Plc...
Woya Digital Announced as Official Marketing Partner of TCR UK for Second Year Running
March 19, 2023 17:01 ET
|
Woya Digital
Chichester, Sussex, March 19, 2023 (GLOBE NEWSWIRE) -- Woya Digital, a leading SEO consultancy, is pleased to announce its second-year partnership with TCR UK as the official marketing partner of...
Immunocore to present four posters at AACR Annual Meeting 2023
March 14, 2023 16:30 ET
|
Immunocore Holdings Limited
Immunocore to present four posters at AACR Annual Meeting 2023 Updated three-year overall survival data for tebentafusp-tebn in previously treated metastatic uveal melanoma Phase 3 data showing...
Immunocore Reports 2022 Financial Results and Provides Business Update
March 01, 2023 07:00 ET
|
Immunocore Holdings Limited
Immunocore Reports 2022 Financial Results and Provides Business Update KIMMTRAK / tebentafusp net revenues of £42 million ($51 million) in Q4 2022 and £117 million ($141 million) in 2022; approved in...